Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical-trial disclosures, patent expiration timelines, or royalty obligations inside Pfizer’s massive SEC filings can feel like searching for a single molecule in a lab. Each 300-page Pfizer annual report 10-K simplified contains dozens of drug-pipeline tables, while every Pfizer quarterly earnings report 10-Q filing updates revenue by therapeutic area and COVID-19 vaccine demand. Add frequent 8-Ks announcing material study results and the picture grows increasingly complex for investors.
That’s where Stock Titan’s AI steps in. Our engine delivers real-time alerts and plain-English summaries the moment a new document hits EDGAR, turning Pfizer SEC filings explained simply into actionable insight. Need Pfizer insider trading Form 4 transactions? You’ll see executive stock trades within minutes, with context on trial milestones. Curious about Pfizer proxy statement executive compensation? Our AI highlights pay tied to oncology breakthroughs. Even Pfizer 8-K material events explained are broken down, so you understand why a Phase 3 success moves the stock.
Whether you’re comparing R&D spend across quarters, tracking Pfizer Form 4 insider transactions real-time, or performing Pfizer earnings report filing analysis, the platform ties each form to the questions professionals actually ask. Use the searchable dashboard to pinpoint:
- Segment revenue trends buried in 10-Qs
- Patent-cliff discussions inside the 10-K
- Pfizer executive stock transactions Form 4 around FDA decisions
Understanding Pfizer SEC documents with AI means no more manual page-turning—just concise insights on drug safety updates, collaboration economics, and global sales dynamics.
Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.
Joseph J. Echevarria, a Director of Pfizer Inc. (PFE), reported an acquisition on 09/30/2025 of 1,815.149 phantom stock units that represent deferred director compensation. The filing shows these units were recorded as acquired with a per-share reference price of $25.48 and that 1,815.149 underlying common shares correspond to the units.
The form states these phantom units are deferred compensation that will be settled in cash or common stock at the director's election following the reporting person’s retirement from the Board. After the reported transaction the filing lists 144,989.542 common shares as beneficially owned. The form was signed by an attorney on behalf of Mr. Echevarria on 10/02/2025.
Albert Bourla, Pfizer's Chairman & CEO and a director, reported a transaction dated 09/15/2025 on a Form 4. He acquired 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan; each unit represents one phantom share and is settled in cash following separation from service. The report shows the units are tied to 25 underlying common shares at a reference price of $23.97. Following the reported transaction, the filing shows 730,907 shares beneficially owned in a direct form. The Form 4 was signed on behalf of Mr. Bourla by power of attorney on 09/17/2025.
Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), acquired 24 phantom stock units on 08/29/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and these units are settled in cash upon the reporting persons separation from service or may be transferred into an alternative investment account at any time. The filing shows a transaction price of $24.76 per unit and reports 730,806 shares beneficially owned following the transaction. The Form 4 was signed on 09/03/2025 by counsel Shanice A. Reid on behalf of Mr. Bourla.
Albert Bourla, Pfizer Inc. Chairman & CEO, acquired 24 phantom stock units on 08/15/2025. Each unit represents one phantom share of common stock and the units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. The units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time. Following the reported transaction, the reporting person beneficially owns 730,477 shares (direct).
Pfizer Inc. (PFE) – Form 4 insider filing shows Chairman & CEO Albert Bourla acquired a de minimis 26 phantom stock units on 31-Jul-2025 through the company’s Non-Funded Deferred Compensation and Supplemental Savings Plan (SSP).
• Transaction code: A (acquisition).
• Unit price: $23.29.
• Total value: ≈ $606.
• Post-transaction holdings: 731,620 phantom stock units, held directly (D).
Phantom units are cash-settled and do not alter the public share count; the participant may transfer them into another investment option at any time. No common stock transactions were reported in Table I.
Materiality: The addition represents less than 0.01 % of Bourla’s existing derivative position and has no discernible impact on Pfizer’s capital structure or governance.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
